Translating tumor biology into personalized treatment planning: Analytical performance characteristics of the Oncotype DX® Colon Cancer Assay

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Clark Langone, Kim M ^a   Sangli, Chithra ^b   Krishnakumar, Jayadevi ^a   Watson, Drew ^a  

^a Genomic Health Inc   (United States)

^b ST JUDE MEDICAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; PARAFFIN; TUMOR MARKER;

ACCURACY; ARTICLE; CANCER RECURRENCE; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; RECURRENCE RISK; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; TREATMENT PLANNING; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CANCER STAGING; COLLOID CARCINOMA; COLON RESECTION; COLON TUMOR; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; METHODOLOGY; MOLECULAR DIAGNOSIS; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; TREATMENT OUTCOME; TUMOR RECURRENCE; VALIDATION STUDY;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PARAFFIN EMBEDDING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78650323746     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-691     Document Type: Article

References (52)

1. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
2. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734. 10.1200/JCO.2005.04.7985, 16720680.
3. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
4. National Comprehensive Cancer Network Practice Guidelines in Oncology. , http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
5. Oratz R, Paul D, Cohn A, Sedlacek S. Impact of a commercial reference laboratory test Recurrence Score on decision making in ealry-stage breast cancer. J Oncol Practice 2007, 3:5287-5312.
6. O'Connell M, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens J, Wolmark N. Relationship between tumor gene expression and recurrence in four independant studies of stage II/II colon cancer patients treated with surgery alone and surgery plus 5-FU/LV. J Clin Oncol 2010, 28:3937-3944.
7. Kerr D, Gray R, Quirke P, Watson D, Yothers G, Lavery I, Lee M, O'Connel MA. A quantitative multi-gene RT-qPCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in 4 large studies and results from the independent, prospectively-defined QUASAR calidation study. J Clin Oncol 2009, 27:15s.
8. Clark-Langone KM, Wu JY, Sangli C, Chen A, Snable JL, Nguyen A, Hackett JR, Baker J, Yothers G, Kim C, Cronin MT. Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics 2007, 8:279. 10.1186/1471-2164-8-279, 1994687, 17697383.
9. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164:35-42. 1602211, 14695316.
10. Krouwer JS, Schlain B. A method to quantify deviations from assay linearity. Clin Chem 1993, 39:1689-1693.
11. Clinical Laboratory Standards Institute: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. CLSI document EP6-A ISBN 1-56238-498-8.
12. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
13. Cronin M, Sangli C, Liu M, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC, Watson D. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007, 53:1084-1091. 10.1373/clinchem.2006.076497, 17463177.
14. Allanach K, Mengel M, Einecke G, Sis B, Hidalgo LG, Mueller T, Halloran PF. Comparing microarray versus RT-PCR assessment of renal allograft biopsies: similar performance despite different dynamic ranges. Am J Transplant 2008, 8:1006-1015. 10.1111/j.1600-6143.2008.02199.x, 18416738.
15. Shippy R, Sendera TJ, Lockner R, Palaniappan C, Kaysser-Kranich T, Watts G, Alsobrook J. Performance evaluation of commercial short-oligonucleotide microarrays and the impact of noise in making cross-platform correlations. BMC Genomics 2004, 5:61. 10.1186/1471-2164-5-61, 517929, 15345031.
16. Glas AM, Floore A, Delahaye LJMJ, Witteveen AT, Pover RCF, Bakx N, Lahti-Domenici JST, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LFA, van't Veer LJ. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006, 7:278. 10.1186/1471-2164-7-278, 1636049, 17074082.
17. Ach RA, Floore A, Curry B, Lazar V, Glas AM, Pover R, Tsalenko A, Ripoche H, Cardoso F, d'Assignies MS, Bruhn L, van't Veer LJ. Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. BMC Genomics 2007, 8:148. 10.1186/1471-2164-8-148, 1904205, 17553173.
18. Shi L, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006, 24:1151-1161. 10.1038/nbt1239, 16964229.
19. Shi L, et al. The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics 2008, 9(Suppl 9):S10. 10.1186/1471-2105-9-S9-S10, 2537561, 18793455.
20. Sato F, Tsuchiya S, Terasawa K, Tsujimoto G. Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS ONE 2009, 4:e5540. 10.1371/journal.pone.0005540, 2677665, 19436744.
21. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659. 10.1056/NEJM198612253152606, 3537791.
22. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi J, van de Rijn M, Botstein D, Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:E7. 10.1371/journal.pbio.0020007, 314300, 14737219.
23. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337. 10.1038/nature03096, 15549095.
24. Sugiyama Y, Farrow B, Murillo C, Li J, Watanabe H, Sugiyama K, Evers BM. Analysis of differential gene expression patterns in colon cancer and cancer stroma using microdissected tissues. Gastroenterology 2005, 128:480-486. 10.1053/j.gastro.2004.11.010, 15685558.
25. Chang HY, Nuyten DSA, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102:3738-3743. 10.1073/pnas.0409462102, 548329, 15701700.
26. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401. 10.1038/nrc1877, 16572188.
27. Riss J, Khanna C, Koo S, Chandramouli GVR, Yang HH, Hu Y, Kleiner DE, Rosenwald A, Schaefer CF, Ben-Sasson SA, Yang L, Powell J, Kane DW, Star RA, Aprelikova O, Bauer K, Vasselli JR, Maranchie JK, Kohn KW, Buetow KH, Linehan WM, Weinstein JN, Lee MP, Klausner RD, Barrett JC. Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res 2006, 66:7216-7224. 10.1158/0008-5472.CAN-06-0040, 16849569.
28. Mesker WE, Liefers G, Junggeburt JMC, van Pelt GW, Alberici P, Kuppen PJK, Miranda NF, van Leeuwen KAM, Morreau H, Szuhai K, Tollenaar RAEM, Tanke HJ. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol 2009, 31:169-178.
29. Mesker WE, Junggeburt JMC, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RAEM. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 2007, 29:387-398.
30. Ungefroren H, Groth S, Ruhnke M, Kalthoff H, Fändrich F. Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta. J Biol Chem 2005, 280:2644-2652. 10.1074/jbc.M411925200, 15546867.
31. Anjomshoaa A, Lin Y, Black MA, McCall JL, Humar B, Song S, Fukuzawa R, Yoon H, Holzmann B, Friederichs J, van Rij A, Thompson-Fawcett M, Reeve AE. Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer. Br J Cancer 2008, 99:966-973. 10.1038/sj.bjc.6604560, 2538751, 19238634.
32. Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004, 22:1572-1582. 10.1200/JCO.2004.10.042, 15117979.
33. Salminen E, Palmu S, Vahlberg T, Roberts P, Söderström K. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol 2005, 11:3245-3249.
34. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003, 21:241-250. 10.1200/JCO.2003.05.044, 12525515.
35. Green RA, Kaplan KB. Chromosome instability in colorectal tumor cells is associated with defects in microtubule plus-end attachments caused by a dominant mutation in APC. J Cell Biol 2003, 163:949-961. 10.1083/jcb.200307070, 2173599, 14662741.
36. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170. 10.1016/S0092-8674(00)81333-1, 8861899.
37. Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, Bicknell D, Bodmer WF, Tomlinson IP. APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci USA 2000, 97:3352-3357. 10.1073/pnas.97.7.3352, 16243, 10737795.
38. Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, Lage P, Slors FJM, Leitão CN, Fodde R, Smits R. The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 2002, 11:1549-1560. 10.1093/hmg/11.13.1549, 12045208.
39. Su LK, Barnes CJ, Yao W, Qi Y, Lynch PM, Steinbach G. Inactivation of germline mutant APC alleles by attenuated somatic mutations: a molecular genetic mechanism for attenuated familial adenomatous polyposis. Am J Hum Genet 2000, 67:582-590. 10.1086/303058, 1287518, 10924409.
40. Cheadle JP, Krawczak M, Thomas MW, Hodges AK, Al-Tassan N, Fleming N, Sampson JR. Different combinations of biallelic APC mutation confer different growth advantages in colorectal tumours. Cancer Res 2002, 62:363-366.
41. Tighe A, Johnson VL, Taylor SS. Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. J Cell Sci 2004, 117:6339-6353. 10.1242/jcs.01556, 15561772.
42. Dihlmann S, Gebert J, Siermann A, Herfarth C, von Knebel Doeberitz M. Dominant negative effect of the APC1309 mutation: a possible explanation for genotype-phenotype correlations in familial adenomatous polyposis. Cancer Res 1999, 59:1857-1860.
43. Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P. Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 1997, 57:4624-4630.
44. Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Näthke IS. A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol 2001, 3:429-432. 10.1038/35070123, 11283619.
45. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 1998, 392:300-303. 10.1038/32688, 9521327.
46. Tighe A, Johnson VL, Albertella M, Taylor SS. Aneuploid colon cancer cells have a robust spindle checkpoint. EMBO Rep 2001, 2:609-614. 10.1093/embo-reports/kve127, 1083941, 11454737.
47. Zhang J, Neisa R, Mao Y. Oncogenic Adenomatous polyposis coli mutants impair the mitotic checkpoint through direct interaction with Mad2. Mol Biol Cell 2009, 20:2381-2388. 10.1091/mbc.E08-12-1206, 2675618, 19261806.
48. Kops GJPL, Weaver BAA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005, 5:773-785. 10.1038/nrc1714, 16195750.
49. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B, Hamilton SR. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994, 331:213-221. 10.1056/NEJM199407283310401, 8015568.
50. Choi S, Lee KJ, Bae Y, Min K, Kwon M, Kim K, Rhyu M. Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res 2002, 8:2311-2322.
51. Chang S, Lin J, Lin T, Liang W. Loss of heterozygosity: an independent prognostic factor of colorectal cancer. World J Gastroenterol 2005, 11:778-784.
52. Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B, French AJ, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006, 131:729-737. 10.1053/j.gastro.2006.06.005, 16952542.